Zydus Lifesciences added 1.38% to Rs 891.60 after it received final approval from US Food & Drug Administration (USFDA) for manufacturing and marketing of Isosorbide Mononitrate extended-release tablets.
Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease). The said drug is equivalent to the reference listed drug (RLD), Imdur extended-release tablets.The product will be manufactured at the groups formulation manufacturing facility at Ahmedabad SEZ, India.
According to IQVIA MAT December 2023, Isosorbide Mononitrate extended-release, tablets USP, 30 mg, 60 mg, and 120 mg had estimated annual sales of $47 million in the U.S.
The group now has received 388 approvals and has also filed for over 460 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Also Read
The pharmaceutical company reported 26.76% increase in consolidated net profit of Rs 789.6 crore on 5.83% rise in revenue from operations to Rs 4,343.70 crore in Q3 FY24 over Q3 FY23.
The counter hit an all time high of Rs 893.80 in todays intraday session.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
